Antiviral Combination Therapies Market Size, Share, Analysis, Trends, Growth Report, 2030

Antiviral Combination Therapies Market

Antiviral Combination Therapies Market By Drug Combination (RTI/NNRTI, Integrase Inhibitor/NRTI, NRTI, NRTI/Protease Inhibitor, and Others), By Type (Branded and Generic), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others), And by Region – Global, And Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, And Forecasts 2023 – 2030

Category: Healthcare Report Format : PDF Pages: 204 Report Code: ZMR-5854 Published Date: Aug-2023 Status : Published
Market Size in 2022 Market Forecast in 2030 CAGR (in %) Base Year
USD 40.23 Billion USD 51.47 Billion 3.13% 2022

Antiviral Combination Therapies Market

Antiviral Combination Therapies Industry Perspective:    

The global antiviral combination therapies market size was worth around $40.23 billion in 2022 and is predicted to grow to around $51.47 billion by 2030 with a compound annual growth rate (CAGR) of roughly 3.13% between 2023 and 2030.

Global Antiviral Combination Therapies Market SizeRequest Free Sample

The report analyzes the global antiviral combination therapies market drivers, restraints/challenges, and the effect they have on the demand during the projection period. In addition, the report explores emerging opportunities in the antiviral combination therapies industry.              

Antiviral Combination Therapies Market: Overview

Antiviral combination therapies, additionally known as aggregate antiviral remedy or CART, are about the use of a couple of antiviral tablets in the aggregate to treat viral infections. This technique involves combining distinct antiviral medications that focus on numerous aspects of the viral replication cycle or specific viral traces to enhance remedy effectiveness and reduce the chance of drug resistance. The purpose of antiviral aggregate therapy lies in the fact that viruses often possess high mutation chances, permitting them to hastily evolve and increase resistance to single capsules.

By using a mixture of antiviral sellers, every with one-of-a-kind mechanisms of action, the therapy objectives are to inhibit viral replication at a couple of factors simultaneously, minimizing the likelihood of resistance emergence. Antiviral mixture treatment options have been efficaciously used for the remedy of various viral infections, which include HIV/AIDS, hepatitis B and C, herpes simplex virus, and influenza. In the case of HIV/AIDS, a mixture of antiretroviral remedies (CART) has revolutionized the management of the disease, extensively prolonging the lifespan of individuals living with HIV and decreasing the development of AIDS.

Key Insights

  • As per the analysis shared by our research analyst, the global antiviral combination therapies market is estimated to grow annually at a CAGR of around 3.13% over the forecast period (2023-2030).
  • In terms of revenue, the global antiviral combination therapies market size was valued at around $ 40.23 billion in 2022 and is projected to reach $ 51.47 billion, by 2030.
  • The antiviral combination therapies market is experiencing an enormous boom due to the rising occurrence of viral infections including HIV/AIDS, hepatitis, influenza, and herpes.
  • Based on the drug combination, the RTI/NNRTI segment is predicted to capture the largest market share during the forecast period.
  • Based on the type, the branded segment is projected to grow at a significant rate during the forecast period.
  • Based on the distribution channel, the hospital pharmacies segment is growing at a significant rate during the forecast period.
  • Based on region, North America is expected to dominate the market during the forecast period.

Global Antiviral combination therapies market SizeRequest Free Sample

Antiviral Combination Therapies Market: Growth Drivers

Rising Prevalence Of Viral Infections To Drive The Global Market Trends

The antiviral combination therapies market growth can be attributed to the rising occurrence of viral infections. Viral infections, including HIV/AIDS, hepatitis, COVID-19, influenza, and herpes, have affected a large proportion of the global population each year. Antiviral combination therapies offer numerous benefits over single-drug treatments, which include more delaying or suppressing of drug resistance. Moreover, antiviral combination therapy has become standard therapy for treating chronic viral ailments such as HCV and HIV. Reportedly, antiviral combination therapies have played a pivotal role in treating HIV by using highly active antiretroviral therapy for reducing drug resistance and restricting the spread of infection. According to NCBI, these combination therapies can effectively treat acute viral infections such as influenza along with reducing drug resistance, suppressing viral replication, acquiring efficiency, and reducing the rate of mortality. All these aforementioned factors will steer the global market surge.

Antiviral Combination Therapies Market: Restraints

Complex Treatment Regimens and Increased Risk of Side Effects to Restrict the global industry trends

Antiviral combination treatment plans regularly involve the simultaneous management of a couple of drugs with distinct dosing schedules and requirements. This complexity can pose demanding situations for patients in adhering to their treatment regimens, in particular for people with constrained health literacy or the ones dealing with a couple of comorbidities. The need to take several medicines at specific instances and cling strictly to the prescribed dosage can lead to non-compliance and treatment interruptions, lowering the general effectiveness of the therapy. This will retard the growth of the antiviral combination therapies industry across the globe.

Antiviral Combination Therapies Market: Opportunities

Emerging Antiviral Combination Therapies for Viral Infections to Open New Growth Avenues for The Global Market

The recent development and emergence of antiviral combination therapies present a significant growth opportunity for the antiviral combination therapies market. Viral infections, which include HIV, hepatitis C, and influenza, can be difficult to deal with due to the capacity of viruses to mutate and develop resistance to single antiviral pills. Combining more than one antiviral retailer with distinct mechanisms of action can enhance treatment efficacy and triumph over drug resistance. The development of recent antiviral mixtures, either through the simultaneous use of multiple tablets or through constant-dose mixture formulations, offers improved treatment outcomes and patient management. Combination healing procedures can goal exclusive levels of the viral replication cycle, inhibit a couple of viral targets, and enhance the overall antiviral effect.

Furthermore, the recent advancements in drug discovery, genomics, and customized remedy have enabled researchers to pick out specific viral goals and design tailored combination treatments. This technique holds promise for addressing viral infections with high chances of drug resistance or restricted treatment alternatives.

 Antiviral Combination Therapies Market: Challenges

Drug Resistance and Continuous Viral Mutation Can Prove To Be A Major Challenge To The Global Industry Surge

As antiviral combination remedies typically involve the use of multiple drugs, every targeting a distinctive component of the viral replication cycle, the intention is to suppress viral replication and prevent the emergence of drug-resistant viral lines. However, regardless of the use of combination therapies, viruses can still acquire mutations that confer resistance to at least one or more of the drugs within the regimen, thereby proving to be a major challenge for the global antiviral combination therapies industry.

Antiviral Combination Therapies Market: Segmentation

The global antiviral combination therapies industry is segmented based on drug combination, type, distribution channel, and region.

Based on its drug combination, the global market is bifurcated into RTI/NNRTI, Integrase Inhibitor/NRTI, NRTI, NRTI/Protease Inhibitor, and Other segments. The RTI/NNRTI segment is predicted to capture the largest market share during the forecast period. The growth can be attributed to RTI/NNRTI aggregate treatments playing an important role in the area of antiviral combination treatments, particularly in the remedy of HIV/AIDS. It helps in halting viral replication. Furthermore, NRTIs, a subset of RTIs, are nucleoside analogs that mimic natural nucleotides present in the viral DNA chain, mainly to terminate the DNA synthesis of viruses.

Based on the type, the global antiviral combination therapies industry is divided into branded and generic segments. The branded segment is expected to dominate the market over the forecast period. Branded medicines are marketed by using pharmaceutical agencies after in-depth research, medical trials, and obtaining regulatory approvals. Pharmaceutical firms are investing significantly in drug discovery, improvement, advertising, and marketing, which have enhanced the demand for branded medicines. All these aforementioned factors will embellish the segmental surge.

Based on the distribution channel, the global antiviral combination therapies market is divided into hospital pharmacies, retail pharmacies, and other segments. The hospital pharmacies segment is expected to dominate the market over the forecast period. Hospital pharmacies play a vital function in the antiviral combination therapies market, in particular with the control and distribution of complex antiviral medicinal drugs in the medical institution. This hospital pharmacy segmentation can boost the antiviral combination therapies market growth.

Recent Developments:

  • In November 2022, the acquisition will give Gilead get right of entry to Immunomes' pipeline of antiviral compounds, consisting of IMX-0301, a potential treatment for hepatitis B. This acquisition can boost the antiviral combination therapies market.
  • In January 2023, Roche announced the launch of Ronapreve, a combination of two antiviral drugs, basiliximab, and imdevimab, for the treatment industry market. This announcement can boost the antiviral combination therapies market.
  • In February 2023, Atea Pharmaceuticals introduced high-quality results from a Phase 2 clinical trial of AT-527, a capacity remedy for COVID-19. AT-527 is a small molecule that targets the SARS-CoV-2 virus's entry pathway. This new development can boost the antiviral combination therapies market landscape.

Antiviral Combination Therapies Market: Report Scope

Report Attributes Report Details
Report Name Antiviral Combination Therapies Market Report
Market Size in 2022 USD 40.23 Billion
Market Forecast in 2030 USD 51.47 Billion
Growth Rate CAGR of 3.13%
Number of Pages 218
Key Companies Covered Gilead Sciences Inc., ViiV Healthcare, Merck & Co. Inc., AbbVie Inc., Bristol Myers Squibb, Janssen Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc., Roche Holding AG, Cipla Ltd., and Mylan N.V.
Segments Covered By Drug Combination, By Type, By Distribution Channel, and By Region
Regions Covered North America, Europe, Asia Pacific (APAC), Latin America, Middle East, and Africa (MEA)
Base Year 2022
Historical Year 2017 to 2021
Forecast Year 2023 - 2030
Customization Scope Avail customized purchase options to meet your exact research needs. Request For Customization

Antiviral Combination Therapies Market: Regional Analysis

North America is expected to dominate the market during the forecast period

North America is predicted to dominate the global antiviral combination therapies market. The regional market growth can be attributed to a rise in the occurrence of viral infections, well-established healthcare infrastructure, and favorable compensation policies. Additionally, the presence of key pharmaceutical companies and ongoing research studies & development efforts will contribute majorly towards the growth of the market in North America.

Europe is likely to record the fastest CAGR over 2023-2030. The regional industry growth can be attributed to the establishment of advanced healthcare systems, extensive research initiatives, and supportive regulatory frameworks. The increasing adoption of combination therapies, along with the presence of a large patient population base, particularly for HIV/AIDS and hepatitis, will drive industry growth in Europe.

Antiviral Combination Therapies Market: Competitive Analysis

The global antiviral combination therapies market is dominated by players like:

  • Gilead Sciences Inc.
  • ViiV Healthcare
  • Merck & Co. Inc.
  • AbbVie Inc.
  • Bristol Myers Squibb
  • Janssen Pharmaceuticals
  • Boehringer Ingelheim Pharmaceuticals Inc.
  • Roche Holding AG
  • Cipla Ltd.
  • Mylan N.V.

The global antiviral combination therapies market is segmented as follows:

By Drug Combination

  • RTI/NNRTI
  • Integrase Inhibitor/NRTI
  • NRTI
  • NRTI/Protease Inhibitor
  • Others

By Type

  • Branded
  • Generic

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

By Region

  • North America
  • The U.S.
  • Canada
  • Europe
    • France 
    • The UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table Of Content

Methodology

FrequentlyAsked Questions

Antiviral combination therapies, additionally known as aggregate antiviral remedy or CART, are about the use of a couple of antiviral tablets in the aggregate to treat viral infections. This technique involves combining distinct antiviral medications that focus on numerous aspects of the viral replication cycle or specific viral traces to decorate remedy effectiveness and reduce the chance of drug resistance.

The antiviral combination therapies market is experiencing an enormous boom due to the rising occurrence of viral infections such as HIV/AIDS, hepatitis, COVID-19, influenza, and herpes.

According to the report, the global market size was worth around $ 40.23 billion in 2022 and is predicted to grow to around $ 51.47 billion by 2030.

The global antiviral combination therapies market is expected to grow at a CAGR of 3.13% during the forecast period.

The North American antiviral combination therapies market growth is expected to be due to the excessive incidence of viral infections, established healthcare infrastructure, and favorable reimbursement policies.

The global antiviral combination therapies market is dominated by players like Gilead Sciences Inc., ViiV Healthcare, Merck & Co., Inc., AbbVie Inc., Bristol Myers Squibb, Janssen Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Inc., Roche Holding AG, Cipla Ltd., and Mylan N.V.

Choose License Type

  • zion payment modes

HappyClients

Office Address

Contact Us

Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651

Asia Pacific Office

3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008

Contact #

US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com

We Are On Social

Industry Press Release

We Accept

We have secured system to process your transaction.

  • payment methods

Business Hours

Our support available to help you 24 hours a day, five days a week.

Monday - Friday: 9AM - 6PM

Saturday - Sunday: Closed